Chemical and Drug Induced Liver Injury

"Chemical and Drug Induced Liver Injury" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.

Descriptor ID	D056486
MeSH Number(s)	C06.552.195 C25.100.562 C25.723.260
Concept/Terms	Chemical and Drug Induced Liver Injury Chemical and Drug Induced Liver Injury Chemically-Induced Liver Toxicity Chemically-Induced Liver Toxicity Chemically Induced Liver Toxicity Chemically-Induced Liver Toxicities Liver Toxicities, Chemically-Induced Liver Toxicity, Chemically-Induced Toxicities, Chemically-Induced Liver Toxicity, Chemically-Induced Liver Drug-Induced Acute Liver Injury Drug-Induced Acute Liver Injury Drug Induced Acute Liver Injury Liver Injury, Drug-Induced, Acute Acute Liver Injury, Drug-Induced Acute Liver Injury, Drug Induced Hepatitis, Toxic Hepatitis, Toxic Toxic Hepatitis Hepatitides, Toxic Toxic Hepatitides Drug-Induced Liver Disease Drug-Induced Liver Disease Disease, Drug-Induced Liver Diseases, Drug-Induced Liver Drug Induced Liver Disease Drug-Induced Liver Diseases Liver Disease, Drug-Induced Liver Diseases, Drug-Induced Drug-Induced Liver Injury Drug Induced Liver Injury Drug-Induced Liver Injuries Injuries, Drug-Induced Liver Injury, Drug-Induced Liver Liver Injuries, Drug-Induced Liver Injury, Drug-Induced Liver Injury, Drug Induced Hepatitis, Drug-Induced Hepatitis, Drug-Induced Drug-Induced Hepatitides Drug-Induced Hepatitis Hepatitides, Drug-Induced Hepatitis, Drug Induced

Below are MeSH descriptors whose meaning is more general than "Chemical and Drug Induced Liver Injury".

Diseases [C]
Digestive System Diseases [C06]
Liver Diseases [C06.552]
Chemical and Drug Induced Liver Injury [C06.552.195]
Chemically-Induced Disorders [C25]
Drug-Related Side Effects and Adverse Reactions [C25.100]
Chemical and Drug Induced Liver Injury [C25.100.562]
Poisoning [C25.723]
Chemical and Drug Induced Liver Injury [C25.723.260]

Below are MeSH descriptors whose meaning is related to "Chemical and Drug Induced Liver Injury".

Below are MeSH descriptors whose meaning is more specific than "Chemical and Drug Induced Liver Injury".

Chemical and Drug Induced Liver Injury
Chemical and Drug Induced Liver Injury, Chronic

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Chemical and Drug Induced Liver Injury" by people in this website by year, and whether "Chemical and Drug Induced Liver Injury" was a major or minor topic of these publications.

Bar chart showing 100 publications over 30 distinct years, with a maximum of 11 publications in 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1992	0	1	1
1993	1	0	1
1994	1	0	1
1995	3	1	4
1997	1	1	2
1998	1	0	1
1999	0	2	2
2000	0	1	1
2001	1	1	2
2002	1	0	1
2003	0	1	1
2004	3	1	4
2005	2	0	2
2006	0	1	1
2007	0	2	2
2008	3	1	4
2009	1	4	5
2010	1	0	1
2011	1	1	2
2012	3	2	5
2013	6	1	7
2014	3	2	5
2015	4	1	5
2016	7	1	8
2017	5	1	6
2018	5	0	5
2019	7	4	11
2020	4	2	6
2021	3	0	3
2022	1	0	1

Below are the most recent publications written about "Chemical and Drug Induced Liver Injury" by people in Profiles.

Yi JS, Chambers TM, Getz KD, Miller TP, Burrows E, Daves MH, Lupo PJ, Scheurer ME, Aplenc R, Rabin KR, Gramatges MM. A report from the Leukemia Electronic Abstraction of Records Network on risk of hepatotoxicity during pediatric acute lymphoblastic leukemia treatment. Haematologica. 2022 05 01; 107(5):1185-1188.

View in: PubMed
Lu HC, González IA, Byrnes K. Ground-glass hepatocellular inclusions are associated with polypharmacy. Ann Diagn Pathol. 2021 Jun; 52:151740.

View in: PubMed
Daver N, Salhotra A, Brandwein JM, Podoltsev NA, Pollyea DA, Jurcic JG, Assouline S, Yee K, Li M, Pourmohamad T, Samineni D, Sumiyoshi T, Vaze A, Dere RC, Ma C, Cooper J. A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia. Am J Hematol. 2021 05 01; 96(5):E175-E179.

View in: PubMed
Singhal R, Donde H, Ghare S, Stocke K, Zhang J, Vadhanam M, Reddy S, Gobejishvili L, Chilton P, Joshi-Barve S, Feng W, McClain C, Hoffman K, Petrosino J, Vital M, Barve S. Decrease in acetyl-CoA pathway utilizing butyrate-producing bacteria is a key pathogenic feature of alcohol-induced functional gut microbial dysbiosis and development of liver disease in mice. Gut Microbes. 2021 Jan-Dec; 13(1):1946367.

View in: PubMed
Jung YS, Stratton SA, Lee SH, Kim MJ, Jun S, Zhang J, Zheng B, Cervantes CL, Cha JH, Barton MC, Park JI. TMEM9-v-ATPase Activates Wnt/ß-Catenin Signaling Via APC Lysosomal Degradation for Liver Regeneration and Tumorigenesis. Hepatology. 2021 02; 73(2):776-794.

View in: PubMed
Tao G, Huang J, Moorthy B, Wang C, Hu M, Gao S, Ghose R. Potential role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity. Expert Opin Drug Metab Toxicol. 2020 Nov; 16(11):1109-1124.

View in: PubMed
Dougan M, Blidner AG, Choi J, Cooksley T, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson D, Shannon VR, Suarez-Almazor M, Anderson R, Rapoport BL. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. Support Care Cancer. 2020 Dec; 28(12):6129-6143.

View in: PubMed
Regev A, Avigan MI, Kiazand A, Vierling JM, Lewis JH, Omokaro SO, Di Bisceglie AM, Fontana RJ, Bonkovsky HL, Freston JW, Uetrecht JP, Miller ED, Pehlivanov ND, Haque SA, Harrison MJ, Kullak-Ublick GA, Li H, Patel NN, Patwardhan M, Price KD, Watkins PB, Chalasani NP. Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. J Autoimmun. 2020 11; 114:102514.

View in: PubMed
Eskiocak U, Guzman W, Wolf B, Cummings C, Milling L, Wu HJ, Ophir M, Lambden C, Bakhru P, Gilmore DC, Ottinger S, Liu L, McConaughy WK, He SQ, Wang C, Leung CL, Lajoie J, Carson WF, Zizlsperger N, Schmidt MM, Anderson AC, Bobrowicz P, Schuetz TJ, Tighe R. Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity. JCI Insight. 2020 03 12; 5(5).

View in: PubMed
Miller ED, Abu-Sbeih H, Styskel B, Nogueras Gonzalez GM, Blechacz B, Naing A, Chalasani N. Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors. Am J Gastroenterol. 2020 02; 115(2):251-261.

View in: PubMed

People

Explore

Similar Concepts

Top Journals